East Windsor, NJ, United States of America

Jason M Cox

This inventor holds 32 USPTO granted patents and 15 published patent applications and 20 EPO patents, primarily in Kinase Inhibitors. Top assignees: Merck Sharp + Dohme Corp., Kinnate Biopharma Inc.. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jason M Cox. Retrieved from https://idiyas.com/inventor/jason-m-cox

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 32 (Patent Applications = 15)

% Patents Active = 100.0

EPO Patents = 20 (Patent Applications = 34)

Average Co-Inventor Count = 5.1

ph-index = 5

Forward Citations = 69(Granted Patents)

Location History:

East Windsor, NJ (US) (2010 - 2021)
Whitehouse Station, NJ (US) (2020 - 2022)
Rancho Santa Fe, CA (US) (2022 - 2023)
Flemington, NJ (US) (2023)

Company Filing History:

24 out of 2,405

Merck Sharp + Dohme Corp.

patents

8 out of 14

Kinnate Biopharma Inc.

patents

Years Active: 2010-2025

Loading Chart...

Areas of Expertise:

Voltage-Gated Sodium Channels

PDE9 Inhibitors

MEK Kinase

RAF Kinases

GPR120 Agonists

Dipeptidyl Peptidase-IV

Mineralocorticoid Receptor

Nicotinamides

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12247031 - Cyclobutyl pyrazolopyrimidine PDE9 inhibitors (2025-03-11),

2. 12246008 - 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels (2025-03-11),

3. 12195445 - 2-amino-N-heteroaryl-nicotinamides as Na1.8 inhibitors (2025-01-14),

4. 12122800 - Inhibitors of MEK kinase (2024-10-22),

5. 11814384 - Inhibtors of Raf kinases (2023-11-14),

6. 11802122 - 2-oxoimidazolidine-4-carboxamides as NA1.8 inhibitors (2023-10-31),

7. 11780862 - Inhibitors of MEK kinase (2023-10-10),

8. 11753395 - Inhibitors of MET kinase (2023-09-12),

9. 11746095 - Inhibtors of RAF kinases (2023-09-05),

10. 11407737 - Inhibitors of RAF kinases (2022-08-09),

11. 11377438 - 2-amino-n-heteroaryl-nicotinamides as Na1.8 inhibitors (2022-07-05),

12. 11377431 - Inhibitors of RAF kinases (2022-07-05),

13. 11345681 - Inhibitors of fibroblast growth factor receptor kinases (2022-05-31),

14. 11161819 - Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists (2021-11-02),

15. 11028092 - Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors (2021-06-08),

Title: The Innovations of Jason M. Cox: A Pioneering Inventor in Pharmaceutical Sciences

Introduction: Jason M. Cox, located in East Windsor, NJ, is a prolific inventor known for his contribution of 30 patents in the pharmaceutical field. His work focuses on novel compounds and their applications in treating various medical disorders, reflecting his commitment to improving healthcare through innovative inventions.

Latest Patents: Among his most recent patents are "2-amino-N-heteroaryl-nicotinamides as Na1.8 inhibitors," which describe a new class of compounds beneficial for conditions mediated by Na1.8 channel activity, including pain and itch disorders. Additionally, his patent on "Inhibitors of MEK Kinase" elaborates on pharmaceutical compositions and methodologies for using these inhibitors to combat various diseases. Both patents exemplify his innovative approach to tackling complex medical issues.

Career Highlights: Jason M. Cox has made noteworthy contributions while working for major companies, including Merck Sharp & Dohme Corporation and Kinnate Biopharma Inc. His extensive career showcases his dedication to research and development in the pharmaceutical sector.

Collaborations: Throughout his career, Jason has collaborated with talented individuals such as Toufike Kanouni and Ann E. Weber. These partnerships have enriched his work and fostered a creative environment conducive to innovation in drug development.

Conclusion: With a robust portfolio of patents and a commitment to scientific research, Jason M. Cox stands as a significant figure in the pharmaceutical industry. His inventions not only enhance our understanding of complex diseases but also pave the way for future advancements in treatment and management strategies.

Profile summary based on public USPTO records.